Magic Beans 🐿️

Could a single immunotherapy drug help some patients with rectal cancer avoid chemotherapy, radiation, and surgery? On October 19, 2026, the FDA granted accelerated approval to dostarlimab (Jemperli) for adults with stage II or III locally advanced rectal cancer whose tumors are mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). I consider this one of the most important recent developments in precision oncology. Why? Because the goal of cancer treatment is not simply to eliminate a tumor. It is also to preserve the patient's quality of life whenever possible. Traditional treatment for locally advanced rectal cancer can involve chemotherapy, radiation, and major surgery. For some patients, this may mean permanent changes in bowel function, urinary function, sexual health, or fertility. Some may require a permanent colostomy. Now, for a carefully selected group of patients, immunotherapy may offer a different path. Dostarlimab is a PD-1 immune checkpoint inhibitor. Instead of directly killing rapidly dividing cells like conventional chemotherapy, it helps restore the immune system's ability to recognize and attack cancer. But here is the most important scientific distinction. This treatment is NOT appropriate for every patient with rectal cancer. Eligibility depends on tumor biology, specifically dMMR or MSI-H status. This is why molecular testing at diagnosis is increasingly important. And while the early clinical results are extraordinary, accelerated approval does not mean every patient will achieve a durable complete response or safely avoid surgery. Careful response assessment, multidisciplinary management, and long-term surveillance remain essential. My message to patients and families: If you or someone you love has been diagnosed with rectal cancer, ask your oncology team: 1. Has my tumor been tested for mismatch repair deficiency or microsatellite instability? 2. Am I a candidate for immunotherapy? 3. Could treatment potentially preserve my rectum? 4. What monitoring and follow-up would be required? The future of oncology is not necessarily more chemotherapy. It is increasingly about identifying the right treatment for the right tumor, while preserving as much of the patient's life and function as possible. We are entering an era when the molecular characteristics of a tumor may matter as much as the organ where the cancer began. What excites you most about this development: the possibility of organ preservation, the precision of biomarker-directed treatment, or the opportunity to reduce long-term treatment complications? Dr. Alex Ehsan, MD, PhD Hematology–Oncology Free cancer education: dralexehsan.com Source: U.S. FDA, October 19, 2026 — Accelerated approval of dostarlimab for dMMR/MSI-H locally advanced rectal cancer. #Oncology #RectalCancer #Immunotherapy #CancerResearch #PrecisionMedicine #Dostarlimab #CancerEducation #PatientCare